SCHEMBL3139258

SCHEMBL3139258

CC(=O)[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.71
CYP3A4 P08684 4/20 0.71
KMT2A Q03164 4/20 0.71
MEN1 O00255 3/20 0.71
RECQL P46063 2/20 0.71
ALOX15 P16050 2/20 0.71
MAPK1 P28482 2/20 0.71
BRCA1 P38398 1/20 0.71
ESR1 P03372 8/20 0.71
ESR2 Q92731 6/20 0.71
MAPT P10636 5/20 0.71
HSD17B10 Q99714 4/20 0.71
HIF1A Q16665 4/20 0.71
PGR P06401 4/20 0.71
AR P10275 4/20 0.71
SHBG P04278 3/20 0.71
SERPINA6 P08185 3/20 0.71
SLC6A4 P31645 3/20 0.71
SNCA P37840 3/20 0.71
SLC6A3 Q01959 3/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12793146 1.00 LMNA (0.71) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL8432942 1.00 LMNA (0.71) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL8840221 0.91 ESR1 (0.71) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL9097615 0.91 ESR1 (0.71) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL14396235 0.88 ESR1 (0.71) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL9235891 0.88 SRD5A2 (0.76) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL11208412 0.88 ESR1 (0.70) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL8434675 0.87 ESR1 (0.69) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL8434673 0.87 ESR1 (0.69) LMNACYP3A4KMT2AMEN1RECQL
SCHEMBL2169796 0.87 ESR1 (0.74) LMNACYP3A4KMT2AMEN1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6083941-A TREATMENT OF NEUROPATHIC PAIN, DRUG WITHDRAWAL/DEPENDENCY, EPILEPSY, GLAUCOMA, CHRONIC NEURODEGENERATIVE DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, ANXIETY DISORDERS, BRAIN CELL DEATH, ISCHAEMIA, STROKE, TRAUMA TRUSTEES OF BOSTON UNIVERSITY (US) 2000-07-04 US claimed
US-20250051387-A1 STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-02-13 US disclosed
US-12139508-B2 Steroid derivative regulators, method for preparing the same, and uses thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-11-12 US disclosed
CN-114805462-A Steroid derivative regulator and preparation method and application thereof 江苏豪森药业集团有限公司 2022-07-29 CN disclosed
US-11384114-B2 Polymorphic forms of an oxysterol and methods of making them WARSAW ORTHOPEDIC, INC. (US) 2022-07-12 US disclosed
CN-114656514-A Steroid derivative regulator and preparation method and application thereof 江苏豪森药业集团有限公司 2022-06-24 CN disclosed
EP-3827833-B1 METHODS FOR THE SEPARATION AND DETECTION OF AN OXYSTEROL WARSAW ORTHOPEDIC INC (US) 2022-06-15 EP disclosed
US-11324759-B2 Oxysterol-statin compounds for bone growth WARSAW ORTHOPEDIC, INC. (US) 2022-05-10 US disclosed
US-11234991-B2 Methods for the separation and detection of an oxysterol WARSAW ORTHOPEDIC, INC. (US) 2022-02-01 US disclosed
US-20210238218-A1 COMPOUNDS AND METHODS OF MAKING STEROLS USING DIOLS WARSAW ORTHOPEDIC INC (US) 2021-08-05 US disclosed
EP-1405860-B1 Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use STANFORD RES INST INT (US) 2007-02-14 EP disclosed
EP-1405860-A1 Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use SRI INTERNATIONAL (US) 2004-04-07 EP disclosed
EP-1042354-A2 ESTRONE SULFAMATE INHIBITORS OF ESTRONE SULFATASE, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE SRI INTERNATIONAL (US) 2000-10-11 EP disclosed
US-6083941-A TREATMENT OF NEUROPATHIC PAIN, DRUG WITHDRAWAL/DEPENDENCY, EPILEPSY, GLAUCOMA, CHRONIC NEURODEGENERATIVE DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, ANXIETY DISORDERS, BRAIN CELL DEATH, ISCHAEMIA, STROKE, TRAUMA TRUSTEES OF BOSTON UNIVERSITY (US) 2000-07-04 US disclosed
US-6046186-A ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS SRI INTERNATIONAL (US) 2000-04-04 US disclosed
WO-1999033858-A9 ESTRONE SULFAMATE INHIBITORS OF ESTRONE SULFATASE, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE STANFORD RES INST INT (US) 1999-10-28 WO disclosed
WO-1999033858-A2 ESTRONE SULFAMATE INHIBITORS OF ESTRONE SULFATASE, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE SRI INTERNATIONAL (US) 1999-07-08 WO disclosed
EP-0840612-A1 INHIBITION OF NMDA RECEPTOR ACTIVITY BY PREGNENOLONE SULFATE DERIVATIVES TRUSTEES OF BOSTON UNIVERSITY (US) 1998-05-13 EP disclosed
WO-1997003677-A1 INHIBITION OF NMDA RECEPTOR ACTIVITY BY PREGNENOLONE SULFATE DERIVATIVES TRUSTEES OF BOSTON UNIVERSITY (US) 1997-02-06 WO disclosed
US-3939186-A Process for producing ethers of steroids MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12139508-B2 Steroid derivative regulators, method for preparing the same, and uses thereof GABRD, GABRR1, GABRA1 LMNA 3740/4885CYP3A4 105/4885KMT2A 4408/4885
US-11234991-B2 Methods for the separation and detection of an oxysterol OSBP2, NR1H3, OSBP LMNA 554/4885CYP3A4 556/4885KMT2A 4870/4885
US-11324759-B2 Oxysterol-statin compounds for bone growth HMGCR, SOST, OSBP2 LMNA 3608/4885CYP3A4 350/4885KMT2A 4672/4885
US-11384114-B2 Polymorphic forms of an oxysterol and methods of making them HSD3B1, VKORC1L1, VKORC1 LMNA 874/4885CYP3A4 60/4885KMT2A 4813/4885
US-20250051387-A1 STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF GABRD, GABRR1, GABRA1 LMNA 3740/4885CYP3A4 105/4885KMT2A 4408/4885
US-20210238218-A1 COMPOUNDS AND METHODS OF MAKING STEROLS USING DIOLS DHCR7, LSS, HSD17B7 LMNA 1545/4885CYP3A4 131/4885KMT2A 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.